Loading…
Loading…
how do you think about the evolution of pricing as another silencer enters the picture
how critical is it to demonstrate an overall survival benefit in Interpath-001
Are you surprised at all by the low case accruals here? Or is this kind of anticipated
what does this suggest about what you're learning about the product, where it might be best suited to work and your evolving confidence
Are you surprised at all by the low case accruals here? Or is this kind of anticipated
what possible changes have you seen in the past month that has caused the bump to expense guidance already
curious what you make of the debate and how you're trying to mitigate this in your trials going forward
can you outline how you see the commercial opportunity evolving for gMG and what your plans are in Europe
your thoughts on the competitive OX40 ligand data shared thus far and how you believe this potentially competes
How critical is it that the product also hits an overall survival in addition to the DFS you top lined
what is needed in this population for a clinically meaningful benefit to justify advancement in this patient segment?
how you view the risk of potential hypogamma adverse events and how this could ultimately impact the label, if at all